QUCY Company Profile and Key Details

Mainz Biomed N.V. earnings surprise history is a mixed track record. The quarter that ended May 15, 2026, missed forecasts by -99.46%.

Average 10-day trading volume of 2.45 million shares is below the 3-month average of 21.30 million, indicating normal recent market interest.

Mainz Biomed N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.63. This means the shares are trading below this model’s fair value.

Mainz Biomed N.V. (NASDAQ:QUCY) closed at $2.03 USD, losing -$0.07 (-3.33%) from the previous close of $2.10. The stock is currently mid-range between its 52-week high and low $0.30 and $4.88. With a market capitalization of about $25.41 million, Mainz Biomed N.V. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.23). Key stats such as the average daily volume over the past year has been around 909.82 thousand shares, trading with heavier-than-usual volume. Headquartered in Mainz, None, Mainz Biomed N.V. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Guido Baechler, the company employs approximately 26 people and listed since November 05, 2021. Mainz Biomed N.V.

Valuation shows Mainz Biomed N.V. trading at a premium to the broader market with a P/E of -2.93. Our AI forecast model points to short-term strength (37.14% over two weeks), a medium-term rise (32.86% over three months), and a longer-term gain (827.62% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Mainz Biomed N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 37.14%, with price expected at $2.88 by June 22, 2026, within a range of $1.94 to $3.88 3-Month Outlook: Projected rise of 32.86%, reaching $2.79 by September 04, 2026, with a range of $2.73 to $2.84. 1-Year Outlook: Projected gain of 827.62%, with price at $19.48 by June 08, 2027, within a range of $19.38 to $19.59.

Mainz Biomed N.V. trades at a P/E ratio of -2.93, slightly below the S&P 500 average, with a price-to-sales ratio of 91.43 and a price-to-book ratio of 5.39 trading at moderately above to book value. The P/FCF stands at -4.74, also above market averages.